In vitro antifungal activity of biosynthesized selenium nanoparticles using plant extracts and six comparators against clinical Fusarium strains.

Abstract

Background and purpose: Fusarium species are commonly resistant to many antifungal drugs. The limited therapeutic options available have led to a surge of research efforts aimed at discovering novel antifungal compounds in recent decades. This study aimed to assess the in vitro antifungal activity of plant-based biosynthesized selenium nanoparticles (Se NPs) and six comparators against a set of clinical Fusarium strains.

Materials and methods: In vitro antifungal activity of Se NPs synthesized using plant extracts of Allium paradoxum, Crocus caspius, Pistacia vera L. hull, Vicia faba L. hull and Heracleum persicum, as well as six common antifungal drugs, namely voriconazole, itraconazole, amphotericin B, posaconazole, natamycin, and caspofungin were evaluated against 94 clinical Fusarium strains using broth microdilution according to Clinical and Laboratory Standards Institute guideline.

Results: The obtained results were intriguing since all five types of biosynthesized Se NPs demonstrated significantly higher antifungal activity, compared to antifungal drugs. It was found that Se NPs synthesized by V. faba L. hull extract (0.03 μg/ml) had the lowest geometric mean minimum inhibitory concentration value followed by Se NPs synthesized by P. vera L. hull extract (0.25 μg/ml), A. paradoxum extract (0.39 μg/ml), C. caspius extract (0.55 μg/ml), and H. persicum extract (0.9 μg/ml).

Conclusion: Plant-based Se NPs demonstrated supreme antifungal activity and could be considered promising antifungal agents for Fusarium infections. However, tests, such as toxicity and in vivo tests are needed before the product can be used in clinical settings.